Idexx Laboratories reported $4.55B of revenue over the trailing twelve months, +13% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $4.55B (to Q2 2026). Net income: $1.14B, trailing twelve months to Q2 2026. Free cash flow: $1.25B, trailing twelve months to Q2 2026. Operating margin: 32%, trailing twelve months to Q2 2026.

IDXXIdexx Laboratories

Healthcare

$518.01-21% 1Y

$518.01

$504.5952 weeks$766.68

IDXX as reported

Idexx Laboratories reported $4.55B of revenue over the trailing twelve months, +13% on the year before. 11 reported series are charted on this page, each one as filed.

$4.55B

Revenue, trailing twelve months · to Q2 2026 · +13% against the twelve months before

Net income: $1.14B
Net income · +16% year on year · trailing twelve months to Q2 2026
Free cash flow: $1.25B
Free cash flow · +60% year on year · trailing twelve months to Q2 2026
Operating margin: 32%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IDXX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$4.55B	+13%	Q2 2026
Net income	$1.14B	+16%	Q2 2026
EPS	$14.23	+18%	Q2 2026
Gross margin	62%	n/a	Q2 2026
Operating margin	32%	n/a	Q2 2026
Net margin	25%	n/a	Q2 2026
ROE	68%	n/a	Q2 2026
ROA	32%	n/a	Q2 2026
ROIC	50%	n/a	Q2 2026
Free cash flow	$1.25B	+60%	Q2 2026
P/E	36.4	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.